Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has received Orphan Drug Designation from the European Medicines Agency for its treatment SLS-005 in mucopolysaccharidosis type III (Sanfilippo syndrome). This designation complements prior ODD approvals in the US and Europe for other diseases, including Spinocerebellar Ataxia Type 3 and Oculopharyngeal Muscular Dystrophy. SLS-005 has also been granted Fast Track designation for OPMD, indicating expedited development and review.
- Orphan Drug Designation granted for SLS-005 in the EU, enhancing its regulatory standing.
- SLS-005 has previously received ODD in both the US and Europe for multiple rare diseases.
- Fast Track designation for OPMD indicates potential for expedited development.
- None.
NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has been granted Orphan Drug Designation (ODD) for SLS-005 in mucopolysaccharidosis type III (MPS III), Sanfilippo syndrome, from the European Medicines Agency (EMA).
To date, SLS-005 has been granted Orphan Drug Designation in the US and Europe for Sanfilippo syndrome, Spinocerebellar Ataxia Type 3 (SCA3) and Oculopharyngeal Muscular Dystrophy (OPMD) as well as Fast Track designation for OPMD.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content:http://www.prnewswire.com/news-releases/seelos-therapeutics-receives-european-orphan-drug-designation-for-sls-005-trehalose-in-sanfilippo-syndrome-301117916.html
SOURCE Seelos Therapeutics, Inc.
